-+ 0.00%
-+ 0.00%
-+ 0.00%
Tarsus Q2 net sales climb 69% to USD 173.9 million
Share
Listen to the news
Tarsus Q2 net sales climb 69% to USD 173.9 million
  • Tarsus posted Q2 net sales of USD 173.9 million, up 69% year over year.
  • Cash and cash equivalents totaled USD 449.7 million at quarter-end, inclusive of marketable securities.
  • Lifted 2026 net sales guidance to USD 685-705 million; gross margin seen at about 83%.
  • Reiterated 2026 SG&A expense guidance of USD 545-565 million; R&D expense outlook reiterated at USD 160-210 million.
  • Agreed to acquire Alkeus with USD 450 million upfront consideration, split 60% cash and 40% stock; up to USD 350 million in milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending